Tolvaptan manufacturers and suppliers in india

Tolvaptan

Properties

Melting point:: 219-222°C

Boiling point:: 594.4±50.0 °C(Predicted)

Density: 1.311±0.06 g/cm3(Predicted)

storage temp.: 2-8°C

solubility: DMSO: ≥15mg/mL

form: powder

pka: 13.00±0.70(Predicted)

color: white to tan

InChIKey: GYHCTFXIZSNGJT-UHFFFAOYSA-N

SMILES: C(NC1=CC=C(C(N2C3=CC=C(Cl)C=C3C(O)CCC2)=O)C(C)=C1)(=O)C1=CC=CC=C1C

Safety Information

Symbol(GHS): GHS08

Signal word: Warning

Hazard statements: H362-H361

Precautionary statements: P201-P260-P263-P264-P270-P308+P313-P201-P202-P281-P308+P313-P405-P501

WGK Germany: 3

Use

Tolvaptan(SAMSCA) should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., 12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable. Tolvaptan(SAMSCA) is contraindicated in the following conditions: Urgent need to raise serum sodium acutely Inability of the patient to sense or appropriately respond to thirst Hypovolemic hyponatremia Concomitant use of strong CYP 3A inhibitors Anuric patients Hypersensitivity (e.g. anaphylactic shock, rash generalized) to tolvaptan or its components